<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Microsatellite instability (MSI) is a genetic consequence of a MisMatch Repair defect in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We compared clinicopathohistological features with MSI status of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and evaluated prognostic significance of MSI status and BRAF mutation in the group of MSI-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>155 primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> were excised surgically, 2006-2008 </plain></SENT>
<SENT sid="3" pm="."><plain>MSI analysis was carried out using a fluorescence-based pentaplex polymerase chain reaction technique </plain></SENT>
<SENT sid="4" pm="."><plain>BRAF mutation (V600E) was analyzed by direct sequencing in MSI-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>For <z:hpo ids='HP_0000001'>all</z:hpo> patients were evaluated: age, gender, localization, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell type, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation, mucin production, <z:e sem="disease" ids="C1262091" disease_type="Disease or Syndrome" abbrv="">lymphocytic infiltration</z:e> (TILs) and TNM stage </plain></SENT>
<SENT sid="6" pm="."><plain>Patients' disease-free survival (DFS) was compared according to MSI and BRAF status using Kaplan-Meier test </plain></SENT>
<SENT sid="7" pm="."><plain>Of the 155 CRCs, 19 (12.3%) were MSI-H, and 136 (87.7%) were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/L </plain></SENT>
<SENT sid="8" pm="."><plain>BRAF mutations were found in 4 of the MSI-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with MSI-H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> had lower recurrence rate (log rank test; P = 0.04) than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/L group </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with MSI-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and BRAF mutation had worse DFS than MSI-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> without this mutation (log rank test; P = 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>Most of the clinicopathologic characteristics of MSI-H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in Serbian patients are similar to those reported in previous studies </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> phenotype had favourable prognosis, but in those with BRAF mutation higher recurrence rate was observed </plain></SENT>
</text></document>